Akebia Therapeutics, Inc.
AKBAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The $285.4M market capitalization puts AKBA squarely in micro-cap range for its industry. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Market Cap
$285.4M
Beta
0.19
P/E (TTM)
—
P/E (Fwd)
-3.12
EPS (TTM)
$-0.12
EPS (Fwd)
$-0.33
ROE
-109.4%
ROA
-1.1%
Cash
$155.5M
Total Debt
$199.2M
Free CF
$33.6M
52W Change
-66.7%
Annual Financials
Cash vs Debt
Where AKBA stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, AKBA finished 23.58% below its 150-day moving average ($1.23) and 28.79% below its 200-day moving average ($1.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AKBA overbought or oversold?
At the August 28, 2026 close, AKBA's RSI(14) was 53.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Akebia Therapeutics, Inc. carries $199.2M in total debt against $155.5M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $33.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -109.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $292.5M (2022) to $236.2M (2025), a 19% decline worth watching.
With a beta below 0.7, Akebia Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AKBA.